CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of “Buy” by Brokerages

CG Oncology, Inc. (NASDAQ:CGON) has been assigned a consensus rating of “Buy” from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $65.14.

A number of equities analysts recently commented on CGON shares. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of CG Oncology in a research note on Friday, January 10th. TD Cowen started coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $66.00 price target on shares of CG Oncology in a research note on Friday, December 6th.

CG Oncology Stock Down 1.3 %

CGON stock opened at $27.85 on Tuesday. CG Oncology has a 12 month low of $25.77 and a 12 month high of $48.05. The company has a 50-day moving average price of $29.20 and a 200 day moving average price of $33.41.

Insider Activity at CG Oncology

In other CG Oncology news, Director Hong Fang Song sold 700,000 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $28.00, for a total transaction of $19,600,000.00. Following the completion of the sale, the director now owns 3,003,931 shares in the company, valued at $84,110,068. This represents a 18.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $29.66, for a total value of $29,660.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 702,000 shares of company stock worth $19,664,200.

Institutional Trading of CG Oncology

A number of hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new stake in CG Oncology during the fourth quarter worth $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of CG Oncology by 496.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,902 shares of the company’s stock worth $3,611,000 after purchasing an additional 104,780 shares in the last quarter. Woodline Partners LP increased its position in shares of CG Oncology by 3.8% during the fourth quarter. Woodline Partners LP now owns 628,885 shares of the company’s stock worth $18,036,000 after purchasing an additional 22,987 shares in the last quarter. Zimmer Partners LP acquired a new position in shares of CG Oncology during the fourth quarter worth $287,000. Finally, Squarepoint Ops LLC acquired a new position in shares of CG Oncology during the fourth quarter worth $313,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.